Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients who completed the D1002001 study~・Patients who completed the D1002001 study and who are considered by the investigator to be eligible and without safety concerns.~Patients who did not participate in the D1002001 study~* Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.~* Outpatients aged 18 through 74 years at the time of consent~* Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode manic, hypomanic, or mixed with or without rapid cycling disease course (≥ 4 episodes of mood disturbance, but \< 8 episodes in the previous 12 months prior to screening).~Exclusion Criteria:~* Patients with imminent risk of suicide or injury to self, others, or property.~* Patients who are otherwise considered ineligible for the study by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- SM-13496 20-120mg (Type: EXPERIMENTAL): once daily orally SM-13496 20-120 mg flexibly dosed

Based on this trial design, predict the completion outcome and termination type (if applicable).